Abstract:Background: Drug-drug interactions (DDIs) are one of the main causes of adverse reactions related to medications, being responsible for up to 23% of hospital admissions. However, only a few studies have evaluated this problem in elderly Brazilians. Objectives: To determine the prevalence of potential DDIs (PDDIs) in community-dwelling elderly people in Brazil, analyse these interactions with regard to severity and clinical implications, and identify associated factors. Methods: A population-based cross-sectional study was carried out involving 2143 elderly (aged >or=60 years) residents of the metropolitan area of Sao Paulo, Brazil. Data were obtained from the SABE (Saúde, Bem estar e Envelhecimento [Health, Well-Being, and Aging]) survey, which is a multicentre study carried out in seven countries of Latin America and the Caribbean, coordinated by the Pan-American Health Organization. PDDIs were analysed using a computerized program and categorized according to level of severity, onset, mechanism and documentation in the literature. The STATA software statistical package was used for data analysis, and logistic regression was conducted to determine whether variables were associated with PDDIs. Results: Analysis revealed that 568 (26.5%) of the elderly population included in the study were taking medications that could lead to a DDI. Almost two-thirds (64.4%) of the elderly population exposed to PDDIs were women, 50.7% were aged >or=75 years, 71.7% reported having fair or poor health and 65.8% took 2-5 medications. A total of 125 different PDDIs were identified; the treatment combination of an ACE inhibitor with a thiazide or loop diuretic (associated with hypotension) was the most frequent cause of PDDIs (n = 322 patients; 56.7% of individuals with PDDIs). Analysis of the PDDIs revealed that 70.4% were of moderate severity, 64.8% were supported by good quality evidence and 56.8% were considered of delayed onset. The multivariate analysis showed that the risk of a PDDI was significantly increased among elderly individuals using six or more medications (odds ratio [OR] 3.37) and in patients with hypertension (OR 2.56), diabetes mellitus (OR 1.73) or heart problems (OR 3.36). Conclusions: Approximately one-quarter of the elderly population living in Sao Paulo could be taking two or more potentially interacting medicines. Polypharmacy predisposes elderly individuals to PDDIs. More than half of these drug combinations (57.6%, n = 72) were part of commonly employed treatment regimens and may be responsible for adverse reactions that compromise the safety of elderly individuals, especially at home. Educational initiatives are needed to avoid unnecessary risks.

Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors

Complexity of the Therapeutic Regimen in Older Adults with Cancer: Associated Factors

Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?

Assessment of polypharmacy, potentially inappropriate medications, and drug-drug interactions in older patients with cancer

Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients

Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy

Prevalence of polypharmacy, drug-drug interactions, and inappropriate prescription in elderly patients with urological cancers.

Audit of drug–drug interactions and adverse drug reactions due to polypharmacy in older cancer patients: First report from India

Research priorities to address polypharmacy in older adults with cancer

The Association Between Medication Use in Older Women with Early-Stage Operable Primary Breast Cancer and Decision Regarding Primary Treatment

Potentially inappropriate medication use in older patients with breast and colorectal cancer

Effect of polypharmacy and potentially inappropriate medications on physical functional decline among older adults with advanced cancer receiving systemic treatment

Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers

Association of polypharmacy with all‐cause mortality and adverse events among elderly colorectal cancer survivors

Prevalence and predictors of potential drug-food interactions among the elderly using prescription drugs

Comorbidity and polypharmacy in patients with breast cancer

Polypharmacy Management in Older Patients

Drug safety among institutionalized elderly people: potential interactions

Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer

Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study

Diseases Linked to Polypharmacy in Elderly Patients